Access Biotechnology
Growth equityNew York City · Seed–Late Stage · 2 people tracked
Investment thesis
Access Biotechnology believes that sustainable financial returns stem from fundamental value creation in the development of novel medicines that meaningfully impact patient health and society. The firm leverages deep medical and scientific expertise to evaluate opportunities rigorously, supports portfolio companies through long-term holding periods unconstrained by typical venture fund cycles, and partners collaboratively with founders and fellow investors to build companies advancing important therapeutic innovations across diverse disease areas.
Source: firm website, verified Aug 5, 2026.
Team · 2 people
from the firm's website & public directories
What they invest in
from 29 of 32 portfolio companiesBiotech ×29Healthtech ×17Medical Devices ×7AI & Machine Learning ×2Deep Tech ×2Digital Health ×2
HQs:United States×18
Investments · 32 tracked
founders shown can be your intro pathBy year:2024 · 12018 · 12 dated
Apogee Therapeutics develops novel antibody therapeutics targeting biological drivers of inflammatory and immune diseases, aiming to improve on the standard of care.
Biotech
Michael Hendersonin
Co-investorsRA Capital
Arvinas develops targeted protein degradation therapies using its PROTAC (PROteolysis TArgeting Chimeras) platform, which harnesses the body's natural protein disposal system to degrade disease-causing proteins.
BiotechHealthtechNew Haven, US
Sean Cassidy(Executive Officer)Manuel Litchman(Executive Officer, Director)
BoardStephen Squinto(Director)inLiam Ratcliffe(Director)Tim Shannon(Director)inKush Parmar(Director)
Co-investors5AM VenturesCanaan PartnersConnecticut InnovationsNextech InvestRA CapitalSolasta Ventures+1 more
Advancing potentially best-in-class therapeutics for myeloproliferative neoplasms.
BiotechCopenhagen, US
Christopher Cain(Director)Garrett Winslow(Executive Officer)Carl Goldfischer(Director)Lori Firmani(Executive Officer)Peter Harwin(Director)Amit Munshi(Director)
Co-investorsBay City CapitalEIR Ventures
Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.
BiotechHealthtech
John Quisel(Chief Executive Officer)Jean Franchi(Chief Financial Officer)Jonathan Yu(Chief Operating Officer)Will Savage(Chief Medical Officer)Pamela Stephenson(Chief Commercial Officer)Steve Caffé(Chief Regulatory Officer)
Co-investorsAtlas VentureBain Capital Life SciencesForesite CapitalFrazier Life SciencesOrbiMed
Hemab is a biotechnology company developing targeted prophylactic therapies for people with serious bleeding and blood coagulation disorders that lack adequate treatment options.
BiotechHealthtech
Co-investorsAvoro Capital AdvisorsHealthCapNovo HoldingsSofinnova Partners
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies.
BiotechDigital HealthHealthtechMedical DevicesBoulder, US
Jason Leverone(Executive Officer)Samuel Agresta(Executive Officer)Dylan Hartley(Executive Officer)Nicholas Saccomano(Executive Officer, Director)Wendy Johnson(Executive Officer)
BoardIsaac Manke(Director)in
Co-investorsRiverVest Venture PartnersAbingworthACORN BIOVENTURESBoulder VenturesNew Enterprise Associates (NEA)
Spyre Therapeutics is a clinical-stage biotechnology company developing antibody therapies for immunology, aiming for more complete disease control, greater durability, and simpler treatment.
BiotechHealthtech
Co-investorsAisling Capital
Upstream Bio is a clinical-stage biotechnology company developing verekitug, an antagonist that targets the TSLP receptor to inhibit pro-inflammatory signaling.
BiotechHealthtech
Rand Sutherlandin
Co-investorsBain Capital Life SciencesDecheng CapitalOrbiMedTCG CrossoverVenrock Healthcare Capital Partners
Zura Bio is a clinical-stage biotechnology company developing antibody therapies for autoimmune diseases using a dual antagonism strategy that targets multiple immune pathways simultaneously.
BiotechHealthtechLa Jolla, US
Someit Sidhu(Executive Officer, Director)Neil Graham(Director)Gary Whale(Chief Technology Officer)Garry Neil(Director)Michael Howell(Executive Officer)Christopher Cabell(Executive Officer)
Co-investorsTMG Ventures
Santa Ana Bio is a biotech company developing engineered antibody therapeutics that target the immune pathways and cells driving autoimmune and inflammatory diseases.
AI & Machine LearningBiotechHealthtechAlameda, US
Peter Emtage(Founder & CEO)inAlexander Rudensky(Scientific Founder)Richard Flavell(Scientific Founder)Graham Lord(Scientific Founder)Ansuman Satpathy(Scientific Founder)Newman Yeilding(Chief Medical Officer)in
Co-investorsVersant VenturesAndreessen HorowitzGV (Google Ventures)RTW Investments L.P.TPG
Trefoil Therapeutics is a clinical-stage biotechnology company developing therapeutic agents for corneal diseases.
BiotechHealthtechMedical DevicesSan Diego, US
David Eveleth(Executive Officer, Director)Schalon Newton(Executive Officer)
BoardChristy Shaffer(Director)inRalph Bradshaw(Director)
Co-investorsExSight VenturesSolasta VenturesBios PartnersCorrelation VenturesFemHealth VenturesHatteras Venture Partners+2 more
Areteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.
BiotechChapel Hill, US
Robin Walker(Executive Officer)Christopher Courts(Executive Officer)Jorge Bartolome(Executive Officer, Director)
BoardBenjamin Gomez(Director)Adam Koppel(Director)inMichael E. Bozik(Director)
Co-investorsARCH Venture PartnersBain Capital Life SciencesGV (Google Ventures)Maverick CapitalSaturn PartnersViking Global Investors
Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors.
BiotechHealthtechSouth San Francisco, US
Jeremy Bender(Executive Officer, Director)
BoardMichael Gladstone(Director)inDerek DiRocco(Director)inJulie Papanek Grant(Director)inJohn Josey(Director)Daniel Becker(Director)
Co-investorsAtlas VentureCanaan PartnersRA CapitalThe Column Group
Co-investorsAvoro Capital Advisors
The site presents corporate and investor news relating to Novo Nordisk, a pharmaceutical company, including financial reports and clinical trial results for products such as GLP-1 medicines and the hemophilia A treatment denecimig (Mim8).
BiotechHealthtech
Co-investorsBain Capital Life Sciences
Draig Therapeutics is a clinical-stage biotech company developing neuromodulator therapies for neuropsychiatric disorders such as major depressive disorder.
BiotechDeep TechDigital Health
Co-investorsCanaan PartnersSanofi VenturesSR One Capital ManagementSV Health InvestorsBritish Business BankJanus Henderson Investors
BiotechSan Diego, US
Arthur T Suckow(Executive Officer)Arthur Suckow, Ph.D.(Founder)in
Co-investorsExSight VenturesRA Capital
BiotechMedical DevicesNew Haven, US
Scott Phillips(Executive Officer)
BoardTim Shannon(Manager)inLiam Ratcliffe(Manager)
Co-investorsCanaan PartnersConnecticut InnovationsFrazier Life SciencesRA CapitalTaiho Ventures, LLCVida Ventures
Khanda is a biotech company builder that translates validated and emerging biological insights into new biotechnology companies focused on orthogonal, combination-based therapeutic approaches.
Biotech
Latigo Bio is a clinical-stage biopharmaceutical company developing non-opioid pain medicines intended to block pain transmission without addiction risk.
BiotechHealthtechThousand Oaks, US
Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)
BoardBeth Seidenberg(Director)inJim Tananbaum(Director)Deborah Palestrant(Director)inKevin Raidy(Director)
Co-investorsForesite CapitalKern Capital, LLCSanofi Ventures5AM VenturesWestlake Village BioPartners
Mariana Oncology, a Novartis company, develops precision radioligand therapies that deliver radioisotopes to diseased cells while limiting effects on healthy tissue.
BiotechHealthtechMedical Devices
Co-investorsAtlas VentureNextech InvestForbionRA Capital
Discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.
Cambridge, US
Co-investorsDigitalis VenturesSanofi Ventures
Harnesses cutting-edge technologies to design exquisitely selective small molecule therapeutics.
Co-investorsBain Capital Life SciencesLightstone VenturesPfizer Venture InvestmentsRA CapitalSV Health Investors
BiotechCambridge, US
Jo Viney(Executive Officer)Rahul Kakkar(Executive Officer, Director)Anthony Coyle(Executive Officer, Director)Christopher Fuglesang(Director)Donald Frail(Director)Daniel Becker(Director)
Co-investorsPolaris PartnersVersant Ventures
Perfuse Therapeutics is a biotechnology company developing a therapy to improve blood flow to the retina, targeting ocular diseases such as glaucoma and diabetic retinopathy.
BiotechMedical DevicesSan Francisco, US
BoardChristy Shaffer(Director)Chau Khuong(Director)inSevgi Gurkan(Executive Officer, Director, Promoter)in
Co-investorsCatalio Capital Management, LPHatteras Venture PartnersLAVLilly Asia VenturesOrbiMedHatteras
BiotechSouth San Francisco, US
MARTIN BABLER(Executive Officer, Director)
BoardPETER THOMPSON(Director)SRINIVAS AKKARAJU(Director)MICHAEL DYBBS(Director)inSIMEON GEORGE(Director)LEWIS J. SHUSTER(Director)
Co-investorsMission BiocapitalSofinnova VenturesMission Bay CapitalNew Leaf Venture PartnersOrbiMedSamsara BioCapital
Recludix Pharma operates a drug discovery platform that combines custom DNA-encoded libraries (DELs), massively parallel structure-activity relationship analysis, structure-based design, and a family-wide SH2 domain screening panel.
AI & Machine LearningBiotechDeep TechHealthtechSan Diego, US
Nancy Whiting(CEO)
Co-investorsNew Enterprise Associates (NEA)Westlake Village BioPartners
Santa Ana Bio develops engineered antibodies targeting immune system pathways to treat autoimmune and inflammatory diseases.
BiotechMedical DevicesAlameda, US
Peter Emtage(Founder & CEO)inAlexander Rudensky(Scientific Founder)Richard Flavell(Scientific Founder)Graham Lord(Scientific Founder)Ansuman Satpathy(Scientific Founder)
BoardThomas Woiwode(Director)in
Co-investorsAndreessen HorowitzGV (Google Ventures)Versant Venture CapitalVersant Ventures
Talawar Therapeutics develops bispecific antibodies that combine two disease-driving pathways in a single therapy for greater and more durable treatment effect.
Biotech
Steve Migausky(Chief Legal and Administrative Officer)
Surrozen develops multifunctional antibody therapeutics that modulate the Wnt signaling pathway and other disease drivers, using a proprietary antibody-engineering platform.
BiotechHealthtech
Co-investorsThe Column Group
Verona Pharma develops treatments for chronic lung conditions.
BiotechHealthtechLondon
Jan-Anders Karlsson(Executive Officer, Director)Peter Spargo(Executive Officer)Patrick Humphrey(Director)Ken Cunningham(Director)Kenneth Newman(Executive Officer)Anders Ullman(Director)
Co-investorsAisling CapitalAndera PartnersForesite CapitalFrazier Life SciencesNew Enterprise Associates (NEA)Sofinnova Partners+4 more
Vima Therapeutics is a biotech company developing drug treatments for movement disorders such as dystonia and related neurological diseases.
BiotechHealthtechMedical Devices
Bernard Ravina(Founder and Chief Executive Officer)Judy Dunn(President of Research & Development)Jessica Fees(Chief Financial Officer)Ariel D. Jasie(Chief Business Officer and General Counsel)Tushar Misra(Chief Technical Officer)
Co-investorsAtlas VentureFrazier Life SciencesAccess IndustriesCanaan Partners
Exits · 10
IPOs and acquisitions across the tracked portfolioApogee TherapeuticsNASDAQ: APGEArvinas Holding Co. LLCNASDAQ: ARVNDamora TherapeuticsNASDAQ: DMRADisc MedicineNASDAQ: IRONHemab TherapeuticsNASDAQ: COAGOnkure Therapeutics IncNASDAQ: OKURSpyre TherapeuticsNASDAQ: SYREUpstream BioNASDAQ: UPBZura BioNASDAQ: ZURADTx Pharmaacq. by Novartis
Portfolio news
latest coverage across their companiesSpyre Therapeutics · investing.com · Aug 18, 2026
Latigo Bio · labusinessjournal.com · Aug 17, 2026
Draig Therapeutics · fiercebiotech.com · Aug 12, 2026
Upstream Bio · stocktitan.net · Aug 11, 2026
Perfuse Therapeutics · bizjournals.com · Jun 29, 2026
Day One Biopharmaceuticals · ad-hoc-news.de · Jun 20, 2026
Trefoil Therapeutics · hatterasvp.com · Jan 9, 2026
Frequently asked questions
- How many investments has Access Biotechnology made?
- Access Biotechnology has 29 tracked investments, 1 of which have exited via acquisition or IPO.
- What stage does Access Biotechnology invest at?
- Access Biotechnology invests at the Seed, Series A, Series B, Growth, Late Stage stages.
- What sectors does Access Biotechnology focus on?
- Access Biotechnology focuses on Biotech.
- Where is Access Biotechnology located?
- Access Biotechnology is headquartered in New York City, US.
- Does Access Biotechnology lead rounds?
- Yes, Access Biotechnology leads investment rounds.
- Who does Access Biotechnology co-invest with?
- Access Biotechnology most often shares deals with Canaan Partners, RA Capital, Atlas Venture, among 43 tracked co-investors.
Images
Co-investors · 5
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
Access Industries is a private holding company and global investment firm founded in 1986 by Len Blavatnik that identifies companies with strong business models and management teams to optimize their value through financial backing and strategic expertise.
Amzak Health is a venture investor focused on first-in-class and best-in-class technologies in the medtech and biotech sectors, partnering closely with portfolio company management teams.
Firms observed investing alongside Access Biotechnology, from public investor directories. Shared companies are the overlap with Access Biotechnology's recorded portfolio.
Similar investors
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Bessemer Venture Partners is a global venture capital firm that partners with entrepreneurs across enterprise, consumer, and healthcare sectors from early stages through growth.